Gilead Sciences Aktie
WKN: 885823 / ISIN: US3755581036
23.06.2023 09:09:36
|
Gilead's Hepcludex Shows Sustained Efficacy, Safety In People With Chronic HDV At Week 96
(RTTNews) - Gilead Sciences, Inc. (GILD) Friday said its hepcludex (bulevirtide) showed sustained efficacy and safety profile at 96 weeks in people with chronic hepatitis delta virus (HDV) infection.
The combined virological and biochemical response rates continued to increase through Week 96 compared to Week 48, with response rates of 55% and 56% with 2 mg and 10 mg hepcludex respectively, Gilead said.
Further, results from an additional analysis showed that participants who had no response or a partial-response at Week 24, achieved virological response by Week 96.
The company presented these new data from the Phase 3 study dubbed MYR301 at the European Association for the Study of the Liver (EASL) Congress 2023.
"This latest data adds to the growing body of evidence establishing bulevirtide as an effective and well tolerated treatment for HDV when used for a longer duration," said Heiner Wedemeyer, MD, Director, Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology at Hannover Medical School.
Hepcludex, which is not approved in the US, is the only approved treatment for HDV in the EU.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Gilead Sciences Inc.mehr Nachrichten
02.05.25 |
NASDAQ Composite Index-Papier Gilead Sciences-Aktie: So viel Verlust wäre bei einem Investment in Gilead Sciences von vor 10 Jahren angefallen (finanzen.at) | |
01.05.25 |
NASDAQ-Handel: NASDAQ 100 beendet den Donnerstagshandel im Plus (finanzen.at) | |
01.05.25 |
NASDAQ 100 aktuell: NASDAQ 100 mit Kursplus (finanzen.at) | |
01.05.25 |
Aufschläge in New York: NASDAQ 100 zeigt sich am Mittag fester (finanzen.at) | |
01.05.25 |
Pluszeichen in New York: Zum Handelsstart Gewinne im NASDAQ 100 (finanzen.at) | |
30.04.25 |
Aufschläge in New York: Börsianer lassen NASDAQ 100 zum Handelsende steigen (finanzen.at) | |
30.04.25 |
NASDAQ 100-Handel aktuell: NASDAQ 100 präsentiert sich zum Start des Mittwochshandels schwächer (finanzen.at) | |
28.04.25 |
Verluste in New York: NASDAQ 100 schlussendlich schwächer (finanzen.at) |
Analysen zu Gilead Sciences Inc.mehr Analysen
Aktien in diesem Artikel
Gilead Sciences Inc. | 91,64 | -1,64% |
|